Dicerna Pharmaceuticals and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases. Dicerna can get up to $201 million in upfront and success-based development and commercialization milestones for an undisclosed target.
A venture capital firm in the Netherlands — backed by some big names in Big Pharma — has raised $95 million in a new fund to fuel European biotech startups.
Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. The company had previously raised $100 million in 2016.
The quest to better detect cancer has made a potentially huge strides. A study out of Yokohama, Japan, has potentially harnessed artificial intelligence to help detect colorectal cancer even before benign tumors become malignant.
Investors in digital health have been busy this year. In the first half of 2017, 188 startups took in $3.5 billion in investments—a record setting amount. It’s not hard to see why. Patients and providers are both looking to digital health tools to get better treatment and improve the relationship dynamic. With all that money flowing into some very intriguing startups, and it’s a good idea to know what the digital health industry holds for us in the coming years.
One Drop, a leading diabetes care management platform announced they are partnering with Fitbit to help people better manage their Diabetes. By working together, Fitbit and One Drop can help make it easier for people to see how physical activity can impact blood glucose levels and make more informed care management decisions. In addition, One Drop will build an App for Fitbit Ionic, bringing One Drop data to the wrist.
Keytruda (pembrolizumab) was the main bright spot for Merck as it weathered blows from the NotPetya cyber attack, new competition and pricing pressures in hepatitis C.
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9 billion acquisition of French cancer firm Advanced Accelerator Applications.
Global efforts to combat tuberculosis (TB) have saved an estimated 53 million lives since 2000 and reduced the TB mortality rate by 37%, according to the Global TB Report 2017, released by WHO today.
Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.